PAH Drug, Opsumit, Seen to Prevent and Treat Lung Disease in a Mouse Model of Scleroderma

Author: Margarida Azevedor
Date Published: February-2016
Source: Pulmonary Hypertension News

Researchers at University College London (UCL) and Actelion Pharmaceuticals presented a study investigating the therapeutic effect of macitentan (Opsumit) in a mouse model of pulmonary hypertension associated with systemic scleroderma (SSc). The presentation, titled “Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with altered TGFbeta/BMPRII Signalling,” took place at the recent 4th Systemic Sclerosis World Congress in Lisbon, Portugal.